SEC Form 4 · accession 0001209191-18-039666

Kezar Life Sciences, Inc. · KZR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jun 25, 2018

Accepted (ET)

Jun 27, 2018 · 4:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001645666

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 25, 2018	C	105,162	—	A	105,162	D
Common Stock^F1,F2	Jun 25, 2018	C	31,481	—	A	136,643	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F2,F1	—	Jun 25, 2018	C	105,162	D	—	—	Common Stock	105,162	0	D
Series B Convertible Preferred Stock^F2,F1	—	Jun 25, 2018	C	31,481	D	—	—	Common Stock	31,481	0	D

F1Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2The members of Aberdare Management Company, LLC are Paul H. Klingenstein and Kathleen R. Bole.